Soundtrack-E: A phase 1 and 2 trial of AZD0486 in people with B-cell lymphomas

This trial aims to assess the treatment AZD0486 in adults with B-cell lymphomas.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06564038

Trial aim and background  

The aim of this trial is to assess how safe and effective the treatment AZD0486 is when given on its own or in combinations with other treatments in people with B-cell lymphomas.

The trial will be in three groups, with each group focusing on different types of lymphoma. The three groups will be:

  1. Relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic leukaemia (SLL)
  2. Relapsed or refractory mantle cell lymphoma (MCL)
  3. Large B-cell lymphoma (DLBCL) or relapsed or refractory B-cell non Hodgkin lymphoma (B-NHL)

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future. 

Who can enter 

Adults with DLBCL or, CLL, SLL or MCL and who have received at least one prior line of therapy may be eligible for this trial.

Locations 

Recruitment is taking place at the following UK locations: 

  • Derriford Hospital, Plymouth
  • London
  • Oxford

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06564038

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.